Summit Therapeutics: Bulls Bet on Ivonescimab as FDA Clock Ticks

SMMT heads into its October 27 earnings release carrying a short score near 74, a contested drug pipeline, and an FDA decision deadline just weeks away.

Options traders are leaning bullish into the print, not defensive. The put/call ratio is running at 0.63, a shade below its 20-day average of 0.67 and in the lower half of its 52-week range of 0.42 to 1.21. That modest skew toward calls sits roughly 0.85 standard deviations below the recent mean, pointing to investors positioning for upside rather than hedging against a miss. The stock itself is down 10% over the past month to $15.47, but has recovered 6% across the past week, suggesting some tactical buying ahead of the release.

Short interest, at 5.4% of free float, has eased rather than built into the event. Shorts fell roughly 3% over the past week to around 41.9 million shares, a gentle unwind rather than a squeeze. Borrow availability is generous at 125%, meaning shares to lend considerably exceed current short positions, and cost to borrow has drifted down 9% on the week to 0.70%. The lending market tells a story of relaxed short conviction, not a high-tension overhang.

The fundamental debate is squarely about ivonescimab. Bulls argue the PD-1xVEGF bispecific has room to carve out a differentiated position if it can deliver clean randomised trial data, even as Merck raises the competitive bar with sac-TMT and MK-2010. The market is large enough, they say, to reward a clearly superior safety and efficacy profile. Bears are less persuaded. They note that HARMONi-3 has yet to replicate HARMONi-6's early PFS separation in the global study, that the mid-trial interim analysis was removed, and that final PFS data has been pushed to the second half of 2026. An FDA decision on November 14 adds a concrete near-term binary. Analyst direction has recently turned more constructive: Jefferies upgraded the stock to Buy in September with a $25 target, and Citigroup lifted its target to $43 on a reiterated Buy. Barclays sits at Equal-Weight with a $20 target. The consensus mean of $22.65 implies roughly 46% upside from current levels, though the range from $11.90 to $43 reflects the degree of clinical uncertainty baked into the stock.

Ownership is heavily concentrated. Co-CEO Robert Duggan holds 71.8% of shares, and both he and co-CEO Mahkam Zanganeh made open-market purchases at $13.12 per share in June, committing roughly $50 million each in discretionary buys. CFO Manmeet Soni also bought at similar levels. That insider cluster, transacted well below the current price, is notable context for the positioning debate. Akeso, the Chinese biotech that originally developed ivonescimab, holds just over 4% of shares and is unchanged on the quarter.

Past earnings have been volatile. The August print produced a 3.7% one-day gain followed by a 15.9% five-day rally, while the July event saw a 7.3% one-day drop that extended to an 8.8% loss over five days. The October print will test whether the latest clinical and regulatory narrative around ivonescimab, particularly on trial execution and the approaching FDA window, justifies the tentative recovery the stock has staged in the past week.